Cargando…

Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

Antibody-drug conjugates (ADCs) are a promising class of immunotherapies with the potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic drugs. ADCs comprise monoclonal antibodies, cytotoxic payloads with inherent antitumor activity, and specialized linkers co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Yurou, Zhou, Xiangxiang, Wang, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180036/ https://www.ncbi.nlm.nih.gov/pubmed/34090506 http://dx.doi.org/10.1186/s13045-021-01097-z

Ejemplares similares

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
por: Barreca, Marilia, et al.
Publicado: (2022)

Recent advances of antibody drug conjugates for clinical applications
por: Zhao, Pengxuan, et al.
Publicado: (2020)

Antibody–drug conjugates: Recent advances in payloads
por: Wang, Zhijia, et al.
Publicado: (2023)

KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo–YAP pathway
por: Chen, Xiaomin, et al.
Publicado: (2023)

Antibody–drug conjugates: Recent advances in linker chemistry
por: Su, Zheng, et al.
Publicado: (2021)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
por: Wang, Yu-Jie, et al.
Publicado: (2017)

Advances and Limitations of Antibody Drug Conjugates for Cancer
por: Mckertish, Candice Maria, et al.
Publicado: (2021)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
por: Wang, Na, et al.
Publicado: (2022)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
por: Kamath, Amrita V., et al.
Publicado: (2015)

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
por: Mohty, Razan, et al.
Publicado: (2021)

Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
por: Nerone, Marta, et al.
Publicado: (2022)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Exploration of the antibody–drug conjugate clinical landscape
por: Maecker, Heather, et al.
Publicado: (2023)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma
por: Fang, Xiaosheng, et al.
Publicado: (2013)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies
por: Samara, Yazeed, et al.
Publicado: (2022)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

Antibody–Drug Conjugates for the Treatment of Acute Pediatric Leukemia
por: Stokke, Jamie L., et al.
Publicado: (2021)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
por: In, Gino K., et al.
Publicado: (2017)

Melanoma Management: From Epidemiology to Treatment and Latest Advances
por: Lopes, Joana, et al.
Publicado: (2022)

Latest Advances in Arbovirus Diagnostics
por: Varghese, Jano, et al.
Publicado: (2023)

Latest Advances in the Development of Eukaryotic Vaults as Targeted Drug Delivery Systems
por: Muñoz-Juan, Amanda, et al.
Publicado: (2019)

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
por: Kim, Eunhee G., et al.
Publicado: (2015)

Latest advances in the treatment of corneal diseases
por: Wang, I-Jong
Publicado: (2015)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Epigenetic targets in B- and T-cell lymphomas: latest developments
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
por: Dan, Nirnoy, et al.
Publicado: (2018)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

Latest advances in aging research and drug discovery
por: Bakula, Daniela, et al.
Publicado: (2019)

Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score
por: Chu, Yurou, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_967s017utlejhiq2nc3nf8bq3v